Status:
COMPLETED
Benign Migratory Glossitis Associated With Antiangiogenic Drugs
Lead Sponsor:
Instituto do Cancer do Estado de São Paulo
Conditions:
Cancer
Geographic Tongue
Eligibility:
All Genders
Brief Summary
Oral clinical descriptions related to adverse events in patients treated with those elective multi-targeted receptor tyrosine kinase inhibitors and a recombinant humanised monoclonal antibody
Detailed Description
Electronical medical and dental records, high-resolution digital photograph were reviewed. Demographic data, medical background, clinical and laboratory information were recorded for each individual c...
Eligibility Criteria
Inclusion
- patient's charts which underwent antiangiogenic targeted drugs
Exclusion
- chemoterapy without angiogenesis inhibitors
Key Trial Info
Start Date :
July 16 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT06988865
Start Date
July 16 2017
End Date
February 1 2024
Last Update
May 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto do Cancer do Estado de São Paulo
São Paulo, São Paulo, Brazil, 01246-000